Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from The United Laboratories International Holdings ( (HK:3933) ).
The United Laboratories International Holdings announced that China’s National Medical Products Administration has approved a clinical trial application for UBT38006 Injection, a self-developed Class 1 innovative long-acting insulin from its subsidiary The United Bio-Technology (Hengqing). Designed with a novel molecular structure that allows reversible binding to human albumin, the drug is intended to deliver a once-weekly dosing regimen by significantly extending its half-life.
The company expects UBT38006 to improve medication adherence for diabetic patients, reduce the burden of frequent injections, and enhance overall quality of life, if successfully developed. Management framed the approval as a major milestone in its diabetes portfolio and a step toward strengthening its competitiveness and innovation in the biopharmaceutical sector, underscoring a continued strategic focus on chronic disease therapies and value creation for shareholders.
The most recent analyst rating on (HK:3933) stock is a Buy with a HK$20.00 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
More about The United Laboratories International Holdings
The United Laboratories International Holdings is a Cayman Islands-incorporated pharmaceutical group listed in Hong Kong, focusing on biopharmaceuticals and chronic disease treatments such as diabetes. Through wholly owned subsidiaries like The United Bio-Technology (Hengqing), the company develops innovative drug candidates aimed at improving patient adherence and clinical outcomes.
Average Trading Volume: 10,269,062
Technical Sentiment Signal: Hold
Current Market Cap: HK$19.04B
For a thorough assessment of 3933 stock, go to TipRanks’ Stock Analysis page.